Share on LinkedInShare on LinkedIn

ARTICLE · 17 SEPTEMBER 2026

FDA-SEC Information Sharing Heightens Focus On Life Science Company Disclosures

Hogan Lovells Cadwalader
Hogan Lovells Cadwalader
Contributor
Hogan Lovells Cadwalader

Hogan Lovells Cadwalader

Hogan Lovells Cadwalader is a global law firm trusted by clients to deliver on complex, high-stakes...

View firm profile
Explore more from Hogan Lovells Cadwalader

The U.S. Securities and Exchange Commission and the U.S. Food and Drug Administration have signed a Memorandum of Understanding establishing a cooperative framework for interagency information sharing...

United StatesGovernment, Public Sector

The U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) have signed a Memorandum of Understanding (MOU) establishing a cooperative framework for interagency information sharing, including the exchange of non-public information. Although the MOU does not impose new disclosure obligations on public companies, it is likely to make non-public FDA information more readily available to SEC staff evaluating whether FDA-regulated public companies' disclosures were false or misleading. In particular, the MOU may enable SEC staff to compare public disclosure against FDA-facing records – including meeting minutes, regulatory correspondence, FDA inspection reports, clinical trial information, safety reporting, and product reviews and approvals – in filing reviews, investigations and enforcement actions. We expect this enhanced information sharing channel to heighten scrutiny of disclosure controls and insider trading procedures involving material

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from